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Summary
The unique glycopeptide antibiotic A47934, produced
by Streptomyces toyocaensis, possesses a nonglyco-
sylated heptapeptide core that is sulfated on the
phenolic hydroxyl of the N-terminal 4-hydroxy-L-phe-
nylglycine residue. Genetic and biochemical experi-
ments confirmed that StaL is a sulfotransferase
capable of sulfating the predicted crosslinked hepta-
peptide substrate to produce A47934 both in vivo and
in vitro. Incubation of purified His6-StaL with various
substrates in vitro revealed substrate specificity and
yielded two sulfo-glycopeptide antibiotics: sulfo-
teicoplanin aglycone and sulfo-teicoplanin. Quantifi-
cation of the antibacterial activity of desulfo-A47934,
A47934, teicoplanin, and sulfo-teicoplanin demon-
strated that sulfation slightly increased the minimum
inhibitory concentration. This unique modification by
sulfation expands glycopeptide diversity with poten-
tial application for the development of new antibiotics.
Introduction
Glycopeptide antibiotics such as vancomycin and teico-
planin have been commonly termed the ‘‘drugs of last
resort’’ for treating infections caused by multidrug-resis-
tant bacteria (e.g., methicillin-resistant Staphyloccoc-
cus aureus). However, the increasing prevalence of nos-
ocomial infections, and the imminent emergence of
community-acquired infections due to vancomycin-
resistant S. aureus and Enterococcus spp., continues
to drive the development of novel antibiotics, including
diverse semisynthetic derivatives of members of this
class.
Glycopeptide antibiotics consist of a heptapeptide
core that is assembled via nonribosomal peptide synthe-
sis, followed by enzymatic modifications of the core
peptide that can include aryl crosslinking, glycosylation,
methylation, hydroxylation, halogenation, acylation, and
sulfation [1, 2]. Streptomyces toyocaensis NRRL 15009
produces the glycopeptide antibiotic A47934 [3–5],
which is unique for two reasons. First, A47934 pos-
sesses the characteristic heptapeptide core, but it is
not glycosylated; thus, it is an ‘‘aglyco’’-glycopeptide
antibiotic. Second, the phenolic hydroxyl of the N-termi-
nal 4-hydroxy-L-phenylglycine (L-HPG) residue of
*Correspondence: wrightge@mcmaster.caA47934 is sulfated [5], resulting in the molecule having
an overall negative charge at physiological pH.
Naturally occurring ‘‘aglyco’’-glycopeptide antibiotics
are rare since they are converted to their glycosylated
form by glycosyltransferases encoded by the producing
organism. To date, only wild-type S. toyocaensis NRRL
15009 and S. virginiae NRRL 15156 have been reported
to produce ‘‘aglyco’’-glycopeptide antibiotics as major
products (i.e., A47934 and A41030A, respectively)
[3, 6]. A41030A is the predominant compound of a com-
plex called A41030 that consists of three glycopeptide
antibiotics and four ‘‘aglyco’’-glycopeptide antibiotics.
However, S. toyocaensis lacks glycosyltransferase-en-
coding genes in the A47934 biosynthetic cluster [7],
and, as a result, it exclusively produces A47934, an
attractive and proven scaffold for novel antibiotic devel-
opment both in vivo and in vitro [8].
Sulfotransferases utilize the sulfate donor 30-phos-
phoadenosine 50-phosphosulfate (PAPS) to catalyze the
transfer of a sulfate group to a hydroxyl acceptor. Eu-
karyotic cytosolic sulfotransferases often can recognize
a variety of molecules as substrates and are known to
play an important role in the detoxification, metabolism,
and regulation of biomolecules [9]. Membrane-associ-
ated sulfotransferases are involved in several signaling
and recognition processes and therefore exhibit stricter
substrate specificity toward complex carbohydrates
and proteins [9]. Several eukaryotic PAPS-dependent
cytosolic sulfotransferases have been well character-
ized, but the putative role of bacterial homologs in the
detoxification of phenols remains to be determined [10].
In fact, the biological significance of only three bacterial
PAPS-dependent sulfotransferases has been estab-
lished. The sulfotransferases NodH and NoeE of Sinorhi-
zobium meliloti are essential for establishing symbiosis
[11, 12], and the sulfotransferase Stf0 of Mycobacterium
tuberculosis has been implicated in virulence [13]. These
three sulfotransferases recognize specific carbohydrate
moieties as substrates, and not aryl compounds.
To date, only two sulfated glycopeptide antibiotics
have been reported: A47934 and UK-68,597 [3, 14]. The
biosynthesis of UK-68,597 in Actinoplanes ATCC 53533
has not been characterized, nor has a putative sulfo-
transferase been identified. However, we have previ-
ously annotated staL as a putative PAPS-dependent
sulfotransferase from analysis of the A47934 biosyn-
thetic gene cluster sequence from S. toyocaensis [7],
and we proposed the sulfation reaction shown in Fig-
ure 1. It has been hypothesized that sulfation occurred
prior to scaffold formation in A47934 biosynthesis [4].
However, analysis of the A47934 nonribosomal peptide
synthetases confirmed that the modules incorporating
the N-terminal amino acid (module 1) and the two central
amino acids (modules 4 and 5) contained adenylation
domains that were highly similar to HPG activation do-
mains [15]. Therefore, sulfation may occur during syn-
thesis of the antibiotic or after the mature crosslinked
peptide has been synthesized. Precedence for sulfation
after antibiotic assembly can be found in the biosynthe-
sis of the sulfated carbapenem antibiotic C-19393 [16].
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172Figure 1. StaL Catalyzes Glycopeptide Antibiotic Sulfation
The predicted de novo substrate desulfo-A47934 is sulfated by the putative sulfotransferase StaL by using the cofactor 30-phosphoadenosine-
50-phosphosulfate (PAPS), resulting in the formation of 30-phosphoadenosine-50-phosphate (PAP) and the sulfo-product A47934.Characterization of StaL will aid in identifying its natural
substrate and thus elucidate the timing of sulfation in
A47934 biosynthesis.
There is much interest in expanding natural product
diversity by using tailoring enzymes or combinatorial
approaches [1, 2, 17–19]. ‘‘Aglyco’’-glycopeptide anti-
biotics represent minimal structures, and both A47934
and A41030A have been proven to be effective scaffolds
for developing novel hybrid glucosyl derivatives by using
cloned vancomycin glycosyltransferases [8]. In a similar
experiment, aglycone derivatives of vancomycin and tei-
coplanin yielded novel hybrid antibiotics by using glyco-
syltransferases cloned from different antibiotic-produc-
ing organisms [20]. This substrate promiscuity exhibited
by glycosyltransferases has been exploited by using
various chemoenzymatic approaches [20–22] and glyco-
randomization strategies [23, 24] to create a large num-
ber of glycosylated variants of vancomycin, teicoplanin,
and their derivatives. Investigating the substrate speci-
ficity of StaL could ultimately provide an opportunity to
expand glycopeptide antibiotic diversity through sulfa-
tion, resulting in unique sulfo-glycopeptide antibiotics.
Using both genetic and biochemical approaches, we
have characterized the putative sulfotransferase StaL
ofS. toyocaensis. The gene inactivation strategy utilizingl-Red recombinase in Escherichia coli [25] has been
modified to successfully create precise in-frame gene
replacements in Streptomyces coelicolor [26]. We ap-
plied this approach to facilitate the replacement of staL
in S. toyocaensis in order to determine the in vivo role
of StaL and to identify its natural substrate. Additionally,
the in vitro sulfotransferase activity and substrate spec-
ificity of purified His6-StaL was investigated. These
experiments have resulted in the creation of two novel
sulfo-glycopeptide antibiotics and provide insight into
the sulfation of glycopeptide antibiotics.
Results
A47934 Production In Vivo Requires staL
A staL replacement strain,S. toyocaensisDstaL::aac(3)IV,
was constructed by optimization of the established
approach [26] and was confirmed by using multiple
PCR amplifications (Figure 2) and Southern analysis
(Figure S1; see the Supplemental Data available with
this article). Fermentation of the strains followed by
LC/ESI-MS analysis of the antibiotic-containing extracts
revealed that the mutant strain no longer synthesized
intact A47934, but, instead, produced an antibacterial
compound with an m/z of 1232.8 (Figure 3). This value isFigure 2. Confirmation of the S. toyocaensis staL Replacement Strain
The genetic organization at the staL locus is depicted in block arrows for each strain, namely, S. toyocaensis wild-type (Strain 1) and
S. toyocaensis DstaL::aac(3)IV (Strain 2). Oligonucleotide primers are shown as black arrows above and below the gene locus. For each strain
(lanes 1 and 2), PCR amplification generated a product corresponding to the size indicated below each gene locus and to the left of the gel
(arrows). Lane 3 contains a GeneRuler 1 kb DNA Ladder (sizes are shown in bp to the right of the gel). Note: Both samples and the DNA ladder
were run on the same gel, but they are shown here as cropped lanes for clarity.
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173Figure 3. StaL Is Required for the In Vivo
Sulfation of Desulfo-A47934
A RP-HPLC trace of the pH-adjusted extracts
from the following strains: (1) S. toyocaensis
wild-type, (2) S. toyocaensis DstaL::aac(3)IV,
(3) S. toyocaensis DstaL::aac(3)IV fC31::staL/
pIJ8600, and (4)S. toyocaensisDstaL::aac(3)IV
fC31::pIJ8600. For each sample, the major
antibiotic peak corresponding to either
A47934 (Rt = 7.0 min) or desulfo-A47934 (Rt
= 8.9 min) was confirmed by LC/ESI-MS
(Table S2). The arrows denote the m/z
[M-H]2 for the compounds of interest.consistent with the desulfo-antibiotic [M-H]2, a com-
pound previously termed A41030A that was isolated
from a complex mixture of glycopeptides fromS. virginiae
[6]. No detectable amount of A47934 was present in
the extract from S. toyocaensis DstaL::aac(3)IV or from
the negative control strain, indicating the exclusive pro-
duction of desulfo-A47934 in the absence of staL.
Complementation of S. toyocaensis DstaL::aac(3)IV
was accomplished by integration of staL/pIJ8600 into
the chromosome in trans at the fC31 att integration
site. The complemented strain, S. toyocaensis DstaL::
aac(3)IV fC31::staL/pIJ8600, now produced almost ex-
clusively an antibiotic with an m/z of 1312.7, a difference
of 80, which is consistent with monosulfation (Figure 3).
The same m/z was observed for A47934 [M-H]2 pro-
duced by wild-type S. toyocaensis.
In Vitro Sulfotransferase Activity of StaL
A staL expression vector was constructed in pET28a,
and His6-StaL was successfully purified as a 30 kDa pro-
tein via Ni-NTA affinity chromatography (Figure 4A).
Subsequent gel filtration chromatography indicated
that purified His6-StaL was a homodimer of approxi-
mately 75 kDa (results not shown). This result is consis-
tent with the reported quaternary structure of most
eukaryotic sulfotransferases [9].
The following phenolic compounds were assessed
as potential substrates of His6-StaL: desulfo-A47934,
teicoplanin aglycone, teicoplanin, vancomycin, ristoce-
tin, 3,5-dihydroxybenzoic acid, phenol, 4-nitrophenol,
rifamycin SV, L-HPG, D-HPG, and L-tyrosine (Tyr). The
linear heptapeptide core of A47934 (H2N-L-HPG-L-Tyr-D-DHPG-D-HPG-L-HPG-D-Tyr-D-DHPG-COOH; DHPG
= 3,5-dihydroxy-D-phenylglycine) was synthesized and
was also tested as an in vitro substrate of His6-StaL.
RP-HPLC analysis of the reactions and controls revealed
that only the desulfo-A47934, teicoplanin aglycone, and
teicoplanin reactions yielded products (Figure 5). These
products exhibited the predicted m/z for A47934, sulfo-
teicoplanin aglycone, and sulfo-teicoplanin when ana-
lyzed by LC/ESI-MS (Table S1; see the Supplemental
Data available with this article online). In addition to
confirming the in vitro sulfotransferase activity of His6-
StaL, these experiments produced two novel sulfo-
glycopeptide antibiotics: sulfo-teicoplanin aglycone and
sulfo-teicoplanin.
The regiospecificity of the sulfate transfer was exam-
ined by using high-field NMR (700 MHz) and LC/ESI-MS/
MS. Assignments for A47934 and desulfo-A47934 via
NMR were complicated by peak overlap and potential
aggregation of desulfo-A47934. However, the MS/MS
fragmentation patterns of the sulfo- and desulfo-antibi-
otics (Table S2) confirmed that monosulfation occurred
on the phenolic hydroxyl of the N-terminal L-HPG resi-
due of desulfo-A47934 (observed m/z of 163.2) to give
the corresponding sulfated fragment in the A47934
spectrum (observed m/z of 245.3). Sulfo-teicoplanin fol-
lowed similar fragmentation patterns to those observed
for A47934 and led to the identification of a common
fragment (observed m/z of 686.1), corresponding to
a monosulfated derivative of the N-terminal tetrapep-
tide. Subsequent fragmentation resulted in loss of the
sulfate ion. Although we could not unambiguously iden-
tify the sulfated residue of sulfo-teicoplanin, the results
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ization of His6-StaL
(A) SDS-polyacrylamide gel of purified His6-
StaL revealed a 30 kDa protein. Lane 1 con-
tains a SigmaMarker Low Range protein
standard (sizes are shown in kDa to the left
of the gel), and a purified His6-StaL sample
is in lane 2.
(B) Kinetic analysis of the in vitro sulfation re-
action with His6-StaL and the substrates de-
sulfo-A47934 and teicoplanin (both at 0.1
mM final concentration). The amount of
A47934 (solid circle) and sulfo-teicoplanin
(open circle) produced at each time point
was quantified by RP-HPLC analysis. The
initial velocity (v0) was calculated to be 2.4
nmol/min and 2.8 3 1022 nmol/min for reac-
tions with desulfo-A47934 and teicoplanin,
respectively.suggest sulfation on either the N-terminal L-HPG resi-
due or the third amino acid residue (i.e., D-DHPG) of tei-
coplanin. However, based on the precedent with the
A47934 fragmentation, we conclude that His6-StaL pref-
erentially sulfates these glycopeptide antibiotics on the
N-terminal L-HPG residue.
Steady-state kinetic studies were performed with
Ni-NTA-purified His6-StaL and either purified desulfo-
A47934 or commercially available teicoplanin as sub-
strates. At high substrate concentrations, the enzyme
exhibited significant inhibition by an unknown mecha-
nism. In an effort to quantify the production of substrate,
we determined the initial velocity (v0) of the sulfotransfer-
ase reaction by using an antibiotic substrate concentra-
tion of 0.1 mM, at which this anomalous kinetic behavior
was not observed (Figure 4B). Under these conditions,
the v0 of the reaction was calculated to be 2.4 nmol/
min and 2.83 1022 nmol/min for desulfo-A47934 and tei-
coplanin, respectively, indicating a 100-fold preference
for desulfo-A47934 over teicoplanin.
Quantification of the Antibacterial Activity of Sulfo-
and Desulfo-Glycopeptides
Construction of the mutant S. toyocaensis DstaL::aac
(3)IV strain allowed facile access to desulfo-A47934
via fermentation and subsequent purification by RP-MPLC. This procedure facilitated the use of desulfo-
A47934 in the substrate specificity studies detailed in
the previous section, as well as for the comparison of
the antibacterial activity of this compound to A47934.
Similarly, access to the overexpressed His6-StaL permit-
ted large-scale reactions with teicoplanin that resulted in
the RP-HPLC purification of microgram quantities of the
novel sulfo-derivative. The minimum inhibitory concen-
tration (MIC) was determined for desulfo-A47934 and
sulfo-teicoplanin according to the NCCLS guidelines
against both vancomycin-sensitive and vancomycin-
resistant bacterial strains (Table 1). A 2-fold increase in
the MIC was observed upon sulfation of desulfo-A47934.
Similar results were obtained for teicoplanin, where sulfa-
tion resulted in at least a 2-fold increase the in MIC.
Discussion
Natural product diversity arises first from the synthesis
of polypeptide, polyketide, or alkaloid scaffolds. These
chemical scaffolds are then modified, sometimes in
combinatorial fashion, through in vivo biosynthetic ap-
proaches that access a variety of modifying enzyme cat-
alysts. Some of the most prevalent modifications include
glycosylation, halogenation, acylation, and alkylation.
These alterations impact the water solubility, size, and
Novel Glycopeptide Antibiotics via Sulfation
175Figure 5. Characterizationof His6-StaLInVitro
(A–C) The structures of the substrates (A) de-
sulfo-A47934, (B) teicoplanin aglycone, and
(C) teicoplanin are shown to the left of each
RP-HPLC trace (Rt = 8.9 min, 9.8 min, and
9.5 min, respectively). Reactions were set
up for each substrate as described in the
Experimental Procedures and contained
purified His6-StaL, whereas the controls did
not. LC/ESI-MS analysis (Table S2) con-
firmed that the product of each reaction
was (A) A47934, (B) sulfo-teicoplanin agly-
cone, and (C) sulfo-teicoplanin (Rt = 7.0,
8.9, and 9.2 min, respectively).receptor affinity of the molecules, in addition to the phar-
macological properties of the subgroup of compounds
that find use as drugs. In some cases, such as the sugar
moieties of the coumarin and glycopeptide antibiotics,
the modifying agents are, in fact, key pharmacophores
of drug activity.
With the exception of aminoglycosylation, these mod-
ifications of natural product scaffolds rarely alter the
charge of the natural product. Modification by sulfation,
however, does provide the means to modify not only
steric bulk and hydrophobicity, but also to introduce
a negative charge. While sulfation is a common solvating
strategy for xenobiotic detoxification in eukaryotes, as-
sessing the biological role of sulfation in prokaryotes
has generally been stalled due to the lack of informationregarding natural substrates, with the exception of three
bacterial carbohydrate sulfotransferases [11–13].
The ‘‘aglyco’’-glycopeptide A47934 is exceptional not
only in the lack of glycosyl modification that is charac-
teristic of this class of antibiotic, but also in the presence
of a sulfate group linked to the phenolic hydroxyl of the
N-terminal L-HPG residue. As a result, and unlike other
antibiotics of the glycopeptide class such as vancomy-
cin and teicoplanin, A47934 possesses an overall nega-
tive charge at pH 7.
Annotation of the A47934 biosynthetic gene cluster
identified a putative PAPS-dependent sulfotransferase,
StaL, encoded by a gene located at the extreme 30 termi-
nus of the gene cluster [7]. The role of this enzyme in
A47934 biosynthesis was confirmed here by in-frame
Chemistry & Biology
176gene replacement of staL, which resulted in the exclu-
sive production of desulfo-A47934. Reintroduction of
staL in trans recapitulated A47934 production, confirm-
ing that the phenotype of the mutant strain was not the
result of polar genetic effects due to the incorporation
of the aac(3)IV resistance marker during gene replace-
ment. This mutant strain provided access to large quan-
tities of the predicted StaL substrate desulfo-A47934,
which was shown to retain antibiotic activity in the ab-
sence of sulfation. This modification is therefore not es-
sential to the antibacterial properties of the compound,
but it does result in a 2-fold increase in the MIC.
Most sulfotransferases are functional as homodimers
[9], and, in this study, recombinant His6-StaL was puri-
fied as a homodimer. StaL also demonstrated the pre-
dicted sulfotransferase activity in vitro, generating
A47934 when incubated with desulfo-A47934 (purified
from the staL replacement strain). Therefore, both the
in vivo and in vitro experiments support sulfation as
the final step in A47934 biosynthesis. Complete in vitro
conversion of desulfo-A47934 to A47934 was accom-
plished by using the recombinant catalyst His6-StaL,
demonstrating the utility of using this enzyme for the in
vitro synthesis of sulfo-compounds. This potential was
exploited with the in vitro synthesis of two novel sulfo-
glycopeptide antibiotics: sulfo-teicoplanin aglycone
and sulfo-teicoplanin. Purification of microgram quanti-
ties of sulfo-teicoplanin permitted analysis of its anti-
bacterial activity and the observation that sulfation of
teicoplanin resulted in at least a 2-fold increase in the
MIC. Thus, modification of glycopeptide antibiotics via
sulfation results in modest increases in the MIC values.
Vancomycin, which lacks an N-terminal L-HPG resi-
due, was not a substrate for StaL, despite the presence
of free para- and meta-hydroxyls in the C-terminal re-
gion of the molecule. Ristocetin was also not a substrate,
even though it possesses a similar peptide backbone as
A47934 and teicoplanin, including an N-terminal L-HPG
residue. However, ristocetin contains a methylated
amino acid (i.e., 3,5-dihydroxyl-4-methylphenylglycine)
that is crosslinked to the N-terminal HPG residue, as
well as an expansion of glycosylation of the central D-
HPG residue. These results demonstrate the unique dis-
criminatory capacity of StaL for glycopeptide antibiotics
(Figure 6). Furthermore, the linear uncrosslinked hepta-
peptide core and both HPG isomers were not substrates
for the enzyme. StaL is therefore unlike other glycopep-
Table 1. Antibacterial Activity of Sulfo- and Desulfo-Glycopeptide
Antibiotics
MIC (mg/ml)
Antibiotic S. aureusa E. faecalis VRE VanB VRE VanA
Vancomycin 0.5 2 8–16 >16
Ristocetin 8 4 >16 >16
Teicoplanin 1–2 1 1 >16
Sulfo-teicoplanin 8 2 4 >16
Teicoplanin
aglycone
0.25 1 4 >16
Desulfo-A47934 0.5 1–2 2 >16
A47934 1 4 4 >16
a Strain abbreviations (left to right) for Staphylococcus aureus ATCC
29213, Enterococcus faecalis ATCC 29212, E. faecalis ATCC 51299,
and an E. faecalis clinical isolate (see Experimental Procedures).tide modifying enzymes (e.g., vancomycin crosslinking
oxidases, [27]) that recognize precursors often still co-
valently linked to nonribosomal peptide synthetases,
but not the free peptide or polyketide scaffolds.
To date, only three other sulfotransferases from bacte-
ria have been characterized. NodH and NoeE are essen-
tial for the symbiosis of S.meliloti [11, 12], and Sft0 is im-
plicated in M. tuberculosis pathogenesis [13]. These
enzymes transfer sulfate to carbohydrate substrates by
using PAPS as a sulfate donor. This study adds StaL as
a bacterial PAPS-dependent sulfotransferase with
a role in natural product biosynthesis. The function of
sulfation in S. toyocaensis is unclear at this time. Sulfa-
tion in eukaryotes is often associated with detoxification
[9], but the antibacterial activity of desulfo-A47934 is only
marginally better than that of the mature sulfo-antibiotic
A47934. Therefore, detoxification is likely not a main
function of sulfation in A47934 biosynthesis. Alterna-
tively, the advantage of sulfation might be increased sol-
ubility since A47934 lacks glycosylated residues. Ulti-
mately, the utility of this sulfating reaction may have
more impact on the pharmacological properties (e.g.,
ADME) of sulfo-glycopeptide antibiotics. This novel re-
action adds to the expanding repertoire of engineering
possibilities for glycopeptide antibiotics. In particular,
the ability to manipulate biosynthetic genes for the fer-
mentation of new glycopeptide scaffolds, coupled with
the in vitro application of modifying enzyme action, can
provide leverage for the development of new antibiotics.
Significance
StaL is a novel sulfotransferase from S. toyocaensis
with the regiospecific capacity to modify glycopeptide
antibiotic scaffolds. This modification expands the re-
action set available for accessorizing glycopeptide an-
tibiotics with the potential to develop new compounds
with sulfated N-terminal L-HPG residues, thus altering
the properties of these compounds (e.g., overall
charge). Glycopeptide antibiotics can already be mod-
ified by glycosylation, acylation, methylation, haloge-
nation, and oxidation. The availability of a sulfation re-
action via StaL adds another level of diversity to this
class of antibiotics that can now be explored in struc-
ture-activity and ADME studies.
The successful combination of genetic and bio-
chemical approaches to generate desulfo-antibiotics
and new sulfo-antibiotics further broadens the signifi-
cance of this work to include a generic strategy for the
synthesis of novel glycopeptide antibiotics. Selective
combinations of in vivo and in vitro approacheswill in-
crease the chemical diversity of this class and can be
applied to other groups of antibiotics. Overall, the use
of a genetically malleable strain, such as S. toyocaen-
sis, with state-of-the-art gene inactivation and replace-
ment strategies demonstrates the power of combining
genetic and biochemical methods in natural product
research.
Experimental Procedures
Compounds and Media
Chemicals were purchased from Sigma-Aldrich Canada, Ltd. or from
BioShop Canada, Inc.; dehydrated media were bought from Becton
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177Figure 6. Substrate Specificity of His6-StaL
(A) Substrates (top to bottom) are desulfo-A47934, teicoplanin aglycone, and teicoplanin.
(B) Compounds that are not His6-StaL substrates (top right to bottom) are the linear heptapeptide (H2N-HPG-Tyr-DHPG-HPG-HPG-Tyr-DHPG-
COOH), HPG, vancomycin, and ristocetin.Dickinson and Company. Oligonucleotide primer synthesis and DNA
sequencing were performed at The MOBIX Lab Central Facility
(McMaster University). To induce the l-Red genes, L-arabinose
was used as reported in [26], and 1 mM isopropyl-b-D-1-thiogalacto-
pyranoside (IPTG) was used to induce expression of His6-StaL.
Antibiotics were used at the following final concentrations (mg/ml):
ampicillin (Amp, 100), kanamycin (Kan, 50; 200 on R2YE), apramycin
(Apr, 50), chloramphenicol (Cam, 25), nalidixic acid (Nal, 25), and
thiostrepton (Tsr, 10). Stock solutions of Nal and Tsr were made
up in 0.3 M NaOH and dimethylformamide, respectively.
The following liquid media for S. toyocaensis contained a spring
baffle to aid in mycelial dispersion: Streptomyces Vegetative Me-
dium (SVM) [28],StreptomycesAntibiotic Medium (SAM) as reported
in [29] plus 1 g yeast extract per liter, Tryptone Soya Broth CM0129
(TSB) (Oxoid, Ltd.) supplemented with 0.5% glycine (stock solution
20% [w/v]), and 2xYeast-Tryptone (2xYT) [30]. Solid media for
S. toyocaensis were the following: Mannitol Soyaflour Agar (MSA;
also known as Soya Flour Medium [SFM]) [30, 31] and R2YE Agar
[30, 32]. Bennett’s Agar (BA) was used to facilitate spore formation
and was modified from the original reference [33] to contain the fol-
lowing components per liter: 10 g potato starch, 2 g casamino acids,
1.8 g yeast extract, 15 g agar, and 2 ml Czapek mineral mix (per 100
ml: 10 g KCl, 10 g MgSO47H2O, 12 g NaNO3, 0.2 g FeSO47H2O, and
200 ml concentrated HCl). LB or SOC [34] were used as growth mediafor E. coli and B. subtilis, whereas BHI and CA-MHB [35] facilitated
growth of S. aureus and E. faecalis strains.
Bacterial Strains
E. coli BL21(DE3) (EMD Biosciences, Inc.) was used as an expres-
sion strain, and E. coli SURE2 (Stratagene) and E. coli TOP10
(Invitrogen Canada, Inc.) were used for cloning purposes. The
REDIRECT technology kit (John Innes Centre) [26] employs E. coli
BW25113 as a recombination host strain, and E. coli ET12567 was
used for intergenic conjugation with S. toyocaensis NRRL 15009.
Dr. E.D. Brown (Department of Biochemistry and Biomedical Sci-
ences, McMaster University) provided the test organism B. subtilis
168 trpC2 (B. subtilis 1A1; Bacillus Genetic Stock Center). An
E. faecalis VanA clinical isolate, donated by Dr. A.K. Petrich (Depart-
ment of Pathology and Molecular Medicine, McMaster University),
and the following American Type Culture Control (ATCC) strains
were employed as test organisms for the quantification of antibacte-
rial activity: Staphylococcus aureus ATCC 29213, E. faecalis ATCC
29212, and E. faecalis ATCC 51299.
B. subtilis 1A1 and S. toyocaensis strains were grown at 30ºC; all
other bacteria were incubated at 37ºC. E. coli pIJ790/BW25113
strains were grown at 30ºC or 37ºC as required [26]. S. toyocaensis
strains were maintained in 20% glycerol at 280ºC, and spore sus-
pensions [30] and frozen stocks of all others strains were preserved
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from either BA or R2YE agar plates were seeded in 25 ml SVM in
a 50 ml Erlenmeyer flask for 2–3 days prior to subculturing into other
media.
Construction of the staL Replacement Cosmid and Strain
The gel-purified EcoRI-HindIII fragment of pIJ773 (see [26]) was
used as a template for the PCR amplification of the 1460 bp oriT
aac(3)IV replacement cassette by using the following primers:
50-GCTGCCCGCCGCGTCGAAGGAACGAGAGGACGCCCGATGAA
CATTCCGGGGATCCGTCGACC-30 and 50-AACATCGAGCGGTGTC
GGACTGTTCAAGCGGGGAATTCATGTAGGCTGGAGCTGCTTC-30.
Underlined sequences anneal to pIJ773, and the nucleotide exten-
sions include either the start or stop codon (shown in bold type) of
staL plus flanking DNA. An additional three nucleotides (italics)
were included due to the overlap of the staK TGA and the staL start
codons. PCR conditions were as follows: 3 min at 94ºC, 30 cycles
(1 min at 94ºC, 1 min at 55ºC, 1.5 min at 72ºC), and 10 min at 72ºC
with 1 U BIOTOOLS DNA Polymerase (Intersciences, Inc.), 5%
DMSO, and 4.5 mM exogenous MgCl2.
The protocol as reported [26] was adhered to with the following
modifications. The pIJ773 EcoRI-HindIII fragment was gel purified
once, and the purified PCR product was treated with DpnI and was
gel purified. SOC was substituted for SOB, and pIJ790/BW25113-
competent cells were induced twice with arabinose. R2YE agar
was used in place of DNA plates for assessing phenotypes ofS. toyo-
caensis colonies. These protocols facilitated the l-Red-mediated
construction of the recombinant plasmid pCepC1 DstaL::aac(3)IV
from pCepC1 [7] and the oriT aac(3)IV PCR product. A restriction
enzyme digest, PCR, and Southern analyses confirmed the con-
struction of the recombinant cosmid. Introduction of this cosmid
into S. toyocaensis via conjugation with E. coli [30, 36] resulted in
the construction of the S. toyocaensis DstaL::aac(3)IV strain, which
was confirmed via PCR and Southern analyses. PCR primers were
50-GGTCTCGCCCGACGGAATGA-30 and 50-AGCGGTGTCGGACTG
TTCAAG C-30, and PCR conditions were as follows: 3 min at 94ºC,
30 cycles (1 min at 94ºC, 1 min at 56.5ºC, 1 min at 72ºC), and 10 min
at 72ºC with 1 U BIOTOOLS DNA Polymerase, 10% DMSO, and 4.5
mM exogenous MgCl2.
Genomic DNA Isolation, Probe Construction,
and Southern Methodology
Wild-type S. toyocaensis and S. toyocaensis DstaL::aac(3)IV were
seeded in SVM, followed by subculturing 200 ml into 20 ml TSB sup-
plemented with 0.5% glycine. After incubation for 2–3 days, cultures
were centrifuged, and the pellets were washed in sterile 10% (w/v)
glycerol and then stored at 220ºC. After thawing, cell pellets were
resuspended, homogenized, and washed twice in SET buffer, fol-
lowed by isolation of the genomic DNA as previously reported [37].
The PCR product used to create the staL complementation
plasmid (see next section) was used to make the staL probe. The
aac(3)IV probe DNA was obtained by PCR by using the EcoRI-HindIII
fragment of pIJ773 as a template, the primers 50-ATTCCGGG
GATCCGTCGACC-30 and 50-TGTAGGCTGGAGCTGCTTC-30, and
PCR conditions as described for the generation of the linear aac(3)IV
replacement fragment (see previous section). The Random Primers
DNA Labeling System (Invitrogen Canada, Inc.) was used to label
200 ng of each PCR product with a-32P-dATP (PerkinElmer Life
and Analytical Sciences). The QIAEX II Gel Extraction kit (QIAGEN,
Inc.) was used to purify the labeled probes.
Three individual restriction enzyme digests (i.e., StuI, XhoI, and
XmnI) were performed in duplicate on 10 mg of each of the following
DNA samples: pCepC1 [7], pCepC1 DstaL::aac(3)IV, and genomic
DNA isolated from wild-type S. toyocaensis and the S. toyocaensis
DstaL::aac(3)IV strain. The 32P-dATP-labeled staL and aac(3)IV
probes were included as controls. Southern hybridization was per-
formed essentially as described in [26, 34]. Phosphor screens
were exposed to the staL and aac(3)IV blots for 1 hr and 24 hr and
were developed on a Typhoon 9200 Variable Mode Imager (Molecu-
lar Dynamics, Amersham Biosciences, Inc.).
Construction of the staL Complementation Vector and Strain
The following primers were used to amplify staL from pCepC1 [7]: 50-
GCTCTAGACATATGAACGGGATGTGCTGGAT-30 and 50-GCTCTAGATCTGGGGAATTCATTCAGCGTATC-30, in which the two putative
start sites (shown in bold type) and the NdeI and BglII sites (under-
lined) are shown. PCR conditions were as follows: 3 min at 94ºC, 30
cycles (1 min at 94ºC, 1 min at 50ºC, 1 min at 72ºC), and 10 min at
72ºC with 1 U BIOTOOLS DNA Polymerase, 5% DMSO, and 3 mM
exogenous MgCl2.
The 820 bp PCR product (NdeI-BglII digested) was ligated into
NdeI-BglII-digested pIJ600 [38]. Restriction digests and sequencing
with the primer 50-CGTGAGGAGGCAGCGTGGAC-30 confirmed the
integrity of staL/pIJ8600. Transformation of this plasmid into
pUZ8002/ET12567 facilitated its subsequent conjugation and inte-
gration [30, 36] into S. toyocaensis DstaL::aac(3)IV, resulting in the
complementation strain S. toyocaensis DstaL::aac(3)IV fC31::staL/
pIJ8600. Similarly, the negative control strain S. toyocaensis DstaL::
aac(3)IV fC31::pIJ8600 was created by using pIJ8600. Confirmation
of these two strains was based on phenotype (i.e., Tsr resistance)
and the antibiotics present in the extract.
Construction of the staL Expression Vector
The following primers were used to amplify staL (containing only the
second putative start site [bolded]) from pCepC1 [7]: 50-GCGAATTC
CATATGTGCTGGATCGCCTCCTACCCG-30 and 50-GCGAATTC
AAGCTTGAATTCATTCAGCGTATCCAT-30, in which the NdeI and
HindIII sites (underlined) and the EcoRI sites (bolded italics) are
shown. PCR conditions were as follows: 3 min at 94ºC, 25 cycles
(1 min at 94ºC, 1 min at 46ºC, and 1.5 min at 72ºC), and 10 min at
72ºC with 1 U VentR DNA Polymerase (New England Biolabs, Ltd.),
2.5% DMSO, and a dNTP mix (70:30; GC:AT). The 820 bp PCR prod-
uct (EcoRI digested) was ligated into EcoRI-digested pUC18 (Fer-
mentas Life Sciences). The NdeI-HindIII fragment containing staL
was subcloned from this plasmid and was ligated into similarly di-
gested pET28a (EMD Biosciences, Inc.). Subsequent restriction
enzyme digests and sequencing (Robarts Research Institute) of the
isolated plasmid confirmed the construction of staL/pET28a.
Expression and Purification of His6-StaL
An overnight culture of staL/pET28a/BL21(DE3) was used to inocu-
late 1 L LB Kan (1:100), which was then grown until an absorbance
of 0.6 at 600 nm was reached (w2 hr). After gentle swirling on ice
for 5 min, IPTG was added to induce expression. The culture was
then incubated at 16ºC for 16–20 hr, after which time the cell pellet
was harvested, washed in 20 ml 0.85% NaCl, and stored at 220ºC.
The cell pellet was thawed on ice and resuspended in 20 ml lysis
buffer containing 1 mM EDTA (pH 8.0), 0.1 mM dithiothreitol (BioShop
Canada, Inc.), and 1 mM phenylmethylsulfonylfluoride in Buffer A
(50 mM HEPES, [pH 7.5], 500 mM NaCl, and 20 mM imidazole). After
three passages through a French Press, the sample was centrifuged,
and the supernatant was loaded onto a 1 ml Ni-NTA Superflow
(QIAGEN, Inc.) column. Purification of His6-StaL was performed at
4ºC with a flow rate of 1 ml/min. Absorbance was monitored at 280
nm. The column was washed with Buffer A, after which the following
linear gradient of Buffer B (50 mM HEPES [pH 7.5], 500 mM NaCl, and
250 mM imidazole) was initiated: 0%–50% B over 25 min, 50% B for
5 min, 50%–100% B over 10 min, and 100% B for 5 min. After SDS-
PAGE and Coomassie staining, fractions containing pure His6-StaL
were pooled, and the protein concentration was determined by using
the Bio-Rad Protein Assay-Dye Reagent Concentrate (Bio-Rad
[Canada] Laboratories, Inc.) [39]. The total yield of His6-StaL was
5 mg (0.3 mg/ml), and the sample was concentrated to 5 mg/ml prior
to assessing sulfotransferase activity (see next section).
Gel filtration chromatography was performed by using a Superdex
75 FPLC column (Amersham Biosciences, Inc.) according to the
manufacturer’s instructions. The buffer consisted of 50 mM HEPES
(pH 7.5) and 200 mM NaCl. The log(molecular weight) of the recom-
mended standards was plotted against Ve/Vo in order to determine
the molecular weight of purified His6-StaL.
In Vitro Sulfation Reactions
For the substrate specificity studies, a control and reaction sample
(30 ml each) was set up in a microcentrifuge tube and contained
the following: 1 mM PAPS, 0.1 mM dithiothreitol, and 25 mM HEPES
(pH 7.5). Substrates tested were desulfo-A47934, teicoplanin agly-
cone, teicoplanin (Haorui Pharma-Chem, Inc.), vancomycin, ristoce-
tin, 3,5-dihydroxybenzoic acid, phenol, 4-nitrophenol, rifamycin SV,
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concentration). To each reaction sample, 5 mg purified His6-StaL (5.2
mM final concentration) was added to initiate the reaction. Both the
controls and reactions were incubated at 30ºC for 20 hr and were
then placed in a boiling water bath for 10 min, followed by incubation
on ice for 10 min and storage at220ºC. RP-HPLC analysis (10 ml) and
LC/ESI-MS (10 ml) were performed on each sample. However, the
substrate specificity samples with nonglycopeptide antibiotic sub-
strates were analyzed solely by LC/ESI-MS.
For the kinetic analysis of His6-StaL, 100 ml reactions were set up in
duplicate and contained the following: 1 mM PAPS, 0.1 mM DTT, 0.1
mM substrate (desulfo-A47934 and teicoplanin), and 15 mM HEPES
(pH 7.5). Reactions were initiated with the addition of 1 mg purified
His6-StaL (1.04 mM final concentration) and were then incubated at
30ºC. For desulfo-A47934, reactions were incubated for 0.25, 0.5,
1.0, 2.5, 5.0, 10, and 30 min. Teicoplanin reactions were incubated
for 0.08, 0.5, 1, 2, 4, and 8 hr. Reactions were stopped as mentioned
for the substrate specificity reactions and then were immediately an-
alyzed by RP-HPLC (100 ml). Additionally, the peak areas of duplicate
desulfo-A47934 and teicoplanin samples were used to generate
a standard curve for each substrate at 280 nm. The amount of prod-
uct formed from each substrate was plotted versus time, and the
initial velocity (v0) of each reaction was calculated by using linear
regression.
Solid-Phase Synthesis of Linear Heptapeptide Core of A47934
Fmoc-L-Tyr(OHBu), Fmoc-D-Tyr(OHBu), Wang resin, and N-hydrox-
ytriazole were purchased from EMD Biosciences, Inc. (Novabio-
chem).D-DHPG was prepared as reported in [40]. Prior to use, amino
acids were Fmoc protected [41]. The synthesis of the linear hepta-
peptide (H2N-L-HPG-L-Tyr-D-DHPG-D-HPG-L-HPG-D-Tyr-D-DHPG-
COOH) was accomplished by using solid-phase peptide synthesis
(0.33 mM scale, 2-[1H-benzotriazole-1-yl]1,1,3,3-tetramethyluro-
niumtetrafluoroborate/hydroxytriazole/diisopropylamine, alternated
by diisopropylcarbodiimide/hydroxytriazole, activation) on Wang
resin derivatized with Fmoc-D-dimethoxyphenylglycine. Side chain
protecting groups were methyl ether for D-DHPG, benzyl ether for
L-HPG, and t-butyl ether for D-Tyr and L-Tyr. D-HPG was used with-
out protection. The assembled peptide was cleaved from the resin by
using a mixture of trifluoroacetic acid (TFA):phenol:triisopropylsilane:
water (95:0.5:0.5:0.2) for 3 hr at room temperature. RP-HPLC afforded
the partially protected peptide in 95% purity. Methyl ether groups
were removed by using a method described in the literature [42].
Benzyl ether was cleaved simultaneously. The final product was
purified by using RP-HPLC and was verified by LC/ESI-MS.
Separation and Analytical Procedures
RP-HPLC was performed with a C18 column (3 mm, 120 A˚, 4.6 3
150mm; Dionex Corporation) and a Dionex GP40 Gradient Pump
system (flow rate of 1 ml/min). Monitoring was performed at 220
and 280 nm.
The extracts from S. toyocaensis and the His6-StaL controls and
reactions were separated by using a dual solvent system consisting
of 20 mM ammonium acetate (Solvent A) and 100% acetonitrile (Sol-
vent B). For each antibiotic tested, a linear gradient of Solvent B was
optimized to separate the sulfated and nonsulfated compounds. The
initial percentage of B (1 min) and the gradient percentage of B (over
9 min) for each antibiotic were as follows: desulfo-A47934 (20%,
20%–25%), teicoplanin aglycone (15%, 15%–30%), teicoplanin
(15%, 15%–45%), vancomycin (10%, 10%–15%), and ristocetin
(5%, 5%–20%).
To purify sulfo-teicoplanin, separation was optimized by using
0.05% TFA in water (Solvent A) and 0.05% TFA in 100% acetonitrile
(Solvent B) and the following program: 20% B for 5 min, 20%–27.5%
B over 20 min. The linear heptapeptide was purified by using the
same solvent system and the following program: 5% B for 1 min
and then an increasing linear gradient to 97% B over 10 min.
LC/ESI-MS data were obtained by using an Agilent 1100 Series LC
system (Agilent Technologies Canada, Inc.) and a QTRAP LC/MS/
MS System (Applied Biosystems/MDS Sciex). The same RP-HPLC
conditions stated for the linear heptapeptide were used for LC/
ESI-MS, but formic acid was used in place of TFA. For the fragmen-
tation analysis by LC/ESI-MS/MS, the experimental conditions were
as follows. Samples were diluted with 50% acetonitrile in water toa final concentration of 5 mg/ml, and 30 ml was directly injected. In-
formation Dependent Acquisition (IDA) enabled ‘‘on the fly’’ acquisi-
tion of the MS/MS spectra during the chromatographic run in a neg-
ative ion mode. Run parameters were as follows: scan rate, 4000
amu/s; settling time, 700 ms; LIT fill time, 20.0 ms; dynamic fill
time, on; Q3 entry barrier, 8.0 V; CUR, 12.0; CAD, medium; ion spray,
4300.0; temperature, 100.0ºC; GS1, 20.0; DP, 240.0; EP, 210.0; and
CE, 210.0 and 220.0.
Antibiotic Extraction from S. toyocaensis Strains
Strains were cultivated in SVM, followed by subculturing 500 ml into
50 ml SAM in a 250 ml Erlenmeyer flask. The culture was centrifuged
after incubation for 6 days, and the wet weight was determined. For
every 1 g of cell mass, 500 ml 1% (v/v) NH4OH was added to extract
the antibiotic; after vortexing and centrifugation, the pH of the super-
natant was adjusted to 7.5 with 1 M HCl (modification of a previously
described method [3]). The extract from each strain was subjected
to analysis by disk-agar diffusion (20 ml) [43], RP-HPLC (10 ml), and
LC/ESI-MS (10 ml).
Purification of Desulfo-A47934 and Sulfo-Teicoplanin
An 85 ml column of octadecyl-functionalized silica gel facilitated de-
sulfo-A47934 purification from 3 ml S. toyocaensis DstaL::aac(3)IV
extract. After washing with 100 ml water, a 5%–50% (v/v) acetonitrile
gradient was initiated. Fractions exhibiting high absorbance read-
ings at 220 and 280 nm, antibacterial activity via disk-agar diffusion
[43], and an RP-HPLC trace corresponding to desulfo-A47934 were
pooled and lyophilized. Resuspension in 200 ml water and adjust-
ment to pH 7.5 yielded a 5 mg/ml solution of desulfo-A47934. The
concentration was determined by using an A47934 standard curve
at 281 nm, and the purity of the sample was confirmed by RP-
HPLC and LC/ESI-MS analyses.
Aliquots of the large-scale in vitro reaction (150 ml) with teicoplanin
and purified His6-StaL were subjected to RP-HPLC, and the eluent
was collected during elution of sulfo-teicoplanin (A2 component).
The collected fractions were concentrated as per desulfo-A47934
procedures and yielded a 1 mg/ml solution of sulfo-teicoplanin.
The concentration was determined by using a teicoplanin standard
curve at 278 nm.
Qualitative and Quantitative Determination of Antibiotic
Activity
The test organism B. subtilis 168/1A1 was employed for qualitative
disk-agar diffusion assays on LB plates [43]. The 0.5 McFarland
standard was prepared by using an inoculated LB plate and the col-
ony suspension method [43]. Plates were incubated at 30ºC for 24
hr. A zone of clearance around a disk was indicative of antibacterial
activity in the sample. To quantify the antimicrobial activity, the MIC
of each sample was determined by using the microdilution broth
method in CA-MHB [35]. The 0.5 McFarland standards were pre-
pared by using the colony suspension method [35] and S. aureus
or E. faecalis strains grown on BHI agar plates. After 24 hr of incuba-
tion at 37ºC, the MIC was determined in mg/ml.
Supplemental Data
Supplemental Data including Southern analysis (Figure S1), MS data
(Table S1), and MS fragmentation analysis (Table S2) are available at
http://www.chembiol.com/cgi/content/full/13/2/171/DC1/.
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